Premia Global Advisors LLC purchased a new stake in Gilead Sciences (NASDAQ:GILD) in the 4th quarter, Holdings Channel reports. The firm purchased 2,781 shares of the biopharmaceutical company’s stock, valued at approximately $198,000.
Several other hedge funds and other institutional investors have also bought and sold shares of GILD. Capital International Investors boosted its holdings in shares of Gilead Sciences by 86.6% in the 3rd quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after buying an additional 5,205,983 shares during the period. Sanders Capital LLC lifted its position in Gilead Sciences by 102.9% in the 4th quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock valued at $757,119,000 after purchasing an additional 5,026,015 shares during the last quarter. Skandinaviska Enskilda Banken AB publ lifted its position in Gilead Sciences by 230.0% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock valued at $399,233,000 after purchasing an additional 3,434,450 shares during the last quarter. CI Global Investments Inc. lifted its position in Gilead Sciences by 5,461.1% in the 4th quarter. CI Global Investments Inc. now owns 3,317,627 shares of the biopharmaceutical company’s stock valued at $237,675,000 after purchasing an additional 3,257,969 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. lifted its position in Gilead Sciences by 53.3% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 9,054,685 shares of the biopharmaceutical company’s stock valued at $648,679,000 after purchasing an additional 3,148,128 shares during the last quarter. 78.35% of the stock is owned by institutional investors and hedge funds.
GILD has been the topic of several recent research reports. Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price objective on the stock. in a research report on Wednesday, January 17th. Jefferies Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $81.19 to $93.00 in a research report on Friday, January 26th. Citigroup upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and cut their price objective for the company from $88.80 to $76.00 in a research report on Tuesday, January 30th. Mizuho set a $95.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Monday, February 5th. Finally, Maxim Group set a $94.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday, February 6th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $88.61.
Shares of GILD opened at $75.68 on Thursday. The company has a market capitalization of $97,384.55, a PE ratio of 8.84, a price-to-earnings-growth ratio of -1.72 and a beta of 1.19. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.67 and a current ratio of 2.74. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $89.54.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business’s revenue was down 18.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.70 EPS. research analysts forecast that Gilead Sciences will post 6.21 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were paid a $0.57 dividend. The ex-dividend date of this dividend was Thursday, March 15th. This represents a $2.28 annualized dividend and a dividend yield of 3.01%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is currently 26.64%.
In other news, Director Gayle E. Wilson sold 60,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $77.92, for a total value of $4,675,200.00. Following the transaction, the director now owns 182,258 shares of the company’s stock, valued at approximately $14,201,543.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robin L. Washington sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total transaction of $401,550.00. Following the completion of the transaction, the chief financial officer now directly owns 23,749 shares in the company, valued at approximately $1,907,282.19. The disclosure for this sale can be found here. Insiders sold a total of 308,600 shares of company stock worth $24,328,226 in the last ninety days. Corporate insiders own 1.16% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “2,781 Shares in Gilead Sciences (GILD) Acquired by Premia Global Advisors LLC” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/19/2781-shares-in-gilead-sciences-gild-acquired-by-premia-global-advisors-llc.html.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.